Pharmacological therapy

Psychiatric Intensive Care, Second Edition

Volumn , Issue , 2008, Pages 50-73

  Okocha, Chike I ^a  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950949086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511543593.008     Document Type: Chapter

References (152)

1. Abrams R. 1992 Electroconvulsive Therapy. New York: Oxford University Press
2. Allison DB, Mentore JH, Heo M et al. 1999 Antipsychotic- induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11): 1686-1696
3. American Psychiatric Association. 1994 Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington, VA: American Psychiatric Association
4. American Psychiatric Association Task Force on ECT. 1990 The Practice of ECT: Recommendations for Treatment, Training, and Privileging. Washington, DC: American Psychiatric Press
5. Atkin K, Kendall F, Gould D. 1996 Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483-488
6. Baastrup PC, Paulsen JC, Schou M, Thomsen K, Amidsen A. 1970 Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet ii: 326-330
7. Ballenger JC, Post RM. 1980 Carbamazepine in manic- depressive illness: a new treatment. Am J Psychiatry 137: 782-790
8. Barnes TRE, Bridges PK. 1980 Disturbed behaviour induced withhigh-dose antipsychoticdrugs. BrMedJ281:274-275
9. Bauer MS, Calabrese JR, Dunner DL. 1994 Multisite data vs analysis: validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 151: 506-515
10. Beasley CM Jr, Tollefson G, Tran P 1996 Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olazapine trial. Neuropsychopharmacology 14:11-1123
11. Beasley CM Jr, Sanger T, Satterlee W. 1996b Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167
12. Beasley CM Jr, Hamilton SH, Crawford AM. 1997 Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsy- chopharmacol 7:125-137
13. Bellack AS, Mueser KT. 1993 Psychosocial treatment for schizophrenia. Schizophr Bull 19: 317-336
14. Bersani G, Bressa GM, Meco G. 1990 Combined 5HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and human neuroendocrine response in a preliminary study with risperidone. Hum Psychophar- macol 5: 225-231
15. Biederman J, Lerner Y, Belmaker RH. 1979 Combination of lithium carbonate and haloperidol in schizoaffective disorder: a controlled study. Arch Gen Psychiatry 36: 327-333
16. Boyer P, Lecrucibier Y, Puech AJ. 1995 Treatment of negative symptoms of schizophrenia with amisulpride. Br J Psychiatry 166: 68-72
17. Bradford JM. 1983 Research on sex offenders. Psychiatr Clin North Am 6(4): 715-731
18. Brandon S, Cowley P, McDonald C, Neville P 1984 Electro- convulsive therapy: results in depressive illness from the Leicestershire trial. Br Med J 288: 22-25
19. Breier A, Meehan K, Birkett M et al. 2002. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59(5): 441-448
20. Brenner HD, Dencker SJ, Goldstein M. 1990 Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551-561
21. Brody D, Adler LA, Kim T. 1990 Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 10: 68-69
22. Cardoni AA. 1995 Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 29:610-618
23. Carman JS, Bigelow LB, Wyatt RJ. 1981 Lithium combined with neuroleptics in chronic schizophrenia and schizoaffective patients. J Clin Psychiatry 42:124-128
24. Castelao JF, Ferrerira L, Gelders YG, Heylen SLE. 1989 The efficacy of the D2 and 5HT2 antagonist risperidone in the treatment of chronic psychoses. An open dose finding study. Schizophr Res 2:411-415
25. Cavallero R, Colombo C, Smeraldi E. 1995 A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol 10: 231-243
26. Chouinard G, Jones B, Remington G. 1993 A canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 35-40
27. Chouinard G, Vainer JL, Belanger MC. 1994 Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 18: 1129-1141
28. Claus A, Bollen J, de Cuyper H. 1992 Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatient: a multi-centre double-blind comparative study. Acta Psychiatr Scand 85: 295-305
29. Cohen NJ, Cohen NH. 1974 Lithium carbonate, haloperidol and irreversible brain damage. J Am Med Assoc 230:1283-1287
30. Committee on the Safety of Medicines. 1990 Cardiotoxic effects of Pimozide. Current Problems No. 29
31. Cooper AJ. 1986 Progestogens in the treatment of male sex offenders: a review. Can J Psychiatry 31(1): 73-79
32. Cooper T. 1996 Clozapine plasma level monitoring: current status. Psychiatr Q 67: 297-311
33. Coppen A, Noguera R, Bailey J. 1971 Prophylactic lithium in affective disorders: a controlled trial. Lancet ii: 326-330
34. Daniel DG, Whitcomb SR. 1998 Treatment of the refractory schizophrenicpatient. JClin Psychiatry 59 [Suppl 1]: 13-19
35. Davidson M, Emsley R, Kramer M et al. 2007 Efficacy, safety and early response of paliperidone extended- release tablets (paliperidone ER): results of a 6 week, randomised, placebo-controlled study. Schizophr Res 10.1016/j.schres.2007.03.003
36. Davis H, Squire L 1984 Protein synthesis and memory. Psychol Bull 96: 518-559
37. Davis JM et al. 1994 Depot antipsychotic drugs: place in therapy. Drugs 47:120-127
38. Devanand DP, Dwork AJ, Hutchinson ER, Bolwig TG, Sackeim HA. 1994 Does electroconvulsive therapy alter brain structure? Am J Psychiatry 151: 957-970
39. Devinsky O, Honigfield G, Patin J. 1991 Clozapin-related seizures. Neurology 41: 369-371
40. Dunner DL, Fieve RR. 1974 Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30: 229-233
41. Emrich HM, Dose M, von Serssen D. 1985 The use of sodium valproate and oxycarbamazepine in patients with affective disorders. J Affect Disord 8: 243-250
42. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. 1991 Episode sequence in bipolar disorder and response to lithium treatment Am J Psychiatry 148: 1237-1239
43. Fieve RR, Kumbaraci T, Dunner DL. 1976 Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 133: 925-930
44. Fink M. 1990 How does ECT work? Neuropsychopharmacology 3: 77-82
45. Fink M. 1994 Indications for the use of ECT. Psychopharm Bull 30(3): 269-280
46. Fontaine K R, Heo M, Harrigan E P etal. 2001 Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101(3): 277-288
47. Fowler NO, McCall D, Chuan T. 1976 Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37: 223-230
48. Freeman CPL, Basson JV, Creighton A. 1978 Double-blind controlled trial of electroconvulsive ttherapy (ECT) and simulated ECT in depressive illness. Lancet i: 738-740
49. Freeman TW, Clothier JL, Passaglia P, Lesem MD. 1992 A double blind comparison of VPA and LI in the treatment of acute mania. Am J Psychiatry 149:108-111
50. Geoff DG, Brotman AW, Waites M, McCormick S. 1990 Trial of fluoxetine added to neuroleptics for treatment resistant schizophrenic patients. Am J Psychiatry 147:492-494
51. Goodnick PJ, Jerry JM. 2002 Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3(12): 1773-1781
52. Goodwin FK, Jamison KR. 1990 Manic-depressive illness. New York: Oxford University Press
53. Gregory S, Shawcross CR, Gill D. 1985 The Nottingham ECT study: a double blind comparison of bilateral, unilateral, and simulated ECT in depressive illness. Br J Psychiatry 146: 520-524
54. Hakola H P, Laulumaa V A. 1982 Carbamazepine in treatment of violent schizophrenics [Letter]. Lancet ii: 13-58
55. Harrington M, Lelliott P, Paton C, Okocha C, Duffett R, Sen- sky T. 2002a The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the United Kingdom. Psychiatr Bull 26:414-418
56. Harrington M, Lelliott P, Paton C, Konsolaki M, Sensky T, Okocha C. 2002b Variation between services in polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 26: 418-420
57. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. 1993 Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383-390
58. Hayes SG. 1989 Longterm use of VPA in primary psychiatric disorders. J Clin Psychiatry 50: 35-39
59. Hegarty J D etal. 1994 One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151: 1409-1416
60. Henderson D C, Cagliero E, Gray C et al. 2000 clozpinel, diabetes mellitus, weight gain and lipid abnormalities: afive-year naturalistic study. Am J Psychiatry 157(6): 975-981
61. Hirsch SR, Barnes TRE. 1994 Clinical use of high-dose neuroleptics. Br J Psychiatry 164: 94-96
62. Hirsch SR, Link CGG, Goldstein JM. 1996 ICI204,636: a new atypical antipsychotic drug. Br J Psychiatry 168 [Suppl 29]: 45-56
63. Hirschowitz J, Casper R, Garver DL. 1980 Lithium response in good prognosis schizophrenia. Am J Psychiatry 137(8): 916-920
64. Ital T, Keskiner A, Heinemann L. 1970 Treatment of resistant schizophrenics with extreme high dosage fluphenazine. Psychosomatics 11: 496-491
65. Johnstone EC, Deakin JFW, Lawler P, Frith CD. 1980 The Northwick Park electroconvulsive therapy trial. Lancet ii: 1317-1320
66. Jusic N, Lader M. 1994 Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 165: 787-791
67. Kallen B, Tandberg A. 1983 Lithium and pregnancy- a cohort study of manic-depressive women. Acta Psychiatr Scand 62:134-139
68. Kane J, Honigfield G, Singer J, MeltzerHY. 1988 The clozaril collaboration study group. Clozapine for the treatment- resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796
69. Kane JM. 1992 Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. Br J Psychiatry Suppl 17: 41-45
70. Kane JM, Marder SR. 1993 Psychopharmacological treatment of schizophrenia. Schizophr Bull 19: 287-302
71. Kane J, Canas F, Kramer M et al. 2006 Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 90:147-161
72. Kapur S. Remington G. 2000 Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. Br Med J 321: 1360-1361
73. Kapur S, Seeman P. 2001 Does fast dissociation from dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158: 360-369
74. Karliner W 1994 Maintenance ECT. Convuls Ther 10: 238-242
75. Karson CN, Weinberger DR, Bigelow L, Wyatt RJ. 1982 Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 139:1627-1628
76. Kemp R, Hayward P, Applewhaite G, Everitt A, David A. 1996 Compliance therapy in psychotic patients: randomised controlled trial. Br Med J 312: 345-349
77. Kessler RC. 1994 Lifetime and 12 month prevalence of DSMI- IIR psychiatric disorders in the United States: results from the National Co-morbidity Survey. Arch Gen Psychiatry 51: 8-20
78. King DJ, Burke M, Lucas RA. 1995 Antipsychotic drug- induced dysphoria. Br J Psychiatry 167:480-482
79. Klein E, Bental E, Lerer B, Belmaker RH. 1984 Carba- mazepine and haloperidol v placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 41:165-170
80. Kramer M, Simpson G, Maciulis V et al. 2007 Paliperi- done extended-release tablets for prevention of symptom recurrence inpatients with schizophrenia: arandom- ized, double-blind, placebo-controlled study. J Clin Psy- chopharmacol 27(1): 6-14
81. Kramlinger KG, Post RM. 1989 Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment- resistant mania. Acta Psychiatr Scand 79: 378-385
82. Kraus T, Haack M, Schuld A et al. 1999 Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156(2): 312-314
83. Kukopulos A, Reginaldi D, Laddomada P, Floric G. 1980 Course of the manic depressive cycle and changes caused by treatment. Pharmacopsych 13:156-167
84. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha, C. 2002 The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 26: 411-414
85. Lieberman JA, Kane JM. 1994 Predictors of response to clozapine. J Clin Psychiatry 55(9): 126-128
86. Lindstedt G, Nilsson LA, Walinder J, Skott A, Ohman R. 1977 On the prevalence, diagnosis and management of lithium induced hypothyroidism in psychiatric patients. Br J Psychiatry 130:452-458
87. Lindstrom LH, Persson E. 1980 Propranolol in chronic schizophrenia controlled study in neuroleptic treated patients. Br J Psychiatry 137: 126-130
88. Little KY, Gay TL, Vore M. 1989 Predictors of response to high-dose antipsychotics in chronic schizophrenics. Psychiatr Res 30:1-9
89. Loo H, Poirer-Littre MF, Theron M. 1997 Amisulpride versus placebo in the medium term treatment of negative symptoms of schizophrenia. Br J Psychiatry 170: 1822
90. Luchins DL. 1984 Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 20(3): 569-571
91. Mann JJ, Kapur S. 1994 Elucidation of the biochemical basis of the antidepressant action of electroconvulsive therapy by human studies. Psychopharmacol Bull 30(3): 445-453
92. Marder SR, Meibach RC. 1994 Risperidone in the treatment of schizophrenia. Am J Psychiatry 15: 825-835
93. Markowitz JS, Candace SB, Moore TR. 1999 Atypical antipsychotics: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 33: 73-85
94. McCreadie RG, MacDonald IM. 1977 High-dose haloperi- dol in chronic schizophrenia. Br J Psychiatry 131: 310-316
95. McCreadie RG, Flanagan WL, McKnight J. 1979 High-dose flupenthixol decanoate in chronic schizophrenia. Br JPsy- chiatry 135: 175-179
96. McEvoy JP, Hogarty GE, Steingard S. 1991 Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739-745
97. Meehan K, Zhang F, David S etal. 2001A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21(4): 389-397
98. Mehtonen OP, Aranko K, Malkonen L. 1991A survey of sudden death associated with the use of antipsychotic or antidepressant drugs. Acta Psychiatr Scand 84: 58-64
99. Meltzer HY. 1991 The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263-287
100. Meltzer HY. 1992 Treatment of the neuroleptic, non- responsive schizophrenic patient. Schizophr Bull 18:515-542
101. Mortimer A. 1997 Treatment of the patient with long-term schizophrenia. Adv Psychiatr Treat 3: 339-346
102. Myers DH, Campbell PL, Cooks NM. 1981 A trial of propranolol in chronic schizophrenia. Br J Psychiatry 139: 118-121
103. Nutt DJ, Glue P 1993 The neurobiology of ECT: animal studies. In: Coffey CE, ed The Clinical Science of Electrocon- vulsive Therapy. Washington DC: American Psychiatric Press, 213-234
104. Okocha CI. 1995 Treating addiction to benzodiazepines. Hospital Update September, 396-401
105. Okocha C I. 1996 Managing anxiety disorders in general practice. Hospital Update November, 415-419
106. Okuma T. 1983 Therapeutic and prophylactic effects of car- bamazepine in bipolar disorders. Psychiatr Clin North Am 6: 147-174
107. Ostrom M etal. 1996 Fatal overdose with citalopram. Lancet 348: 339-340
108. Paris J. 2000 Chronic suicidality among patients with borderline personality disorder. Psychiatr Serv 53: 738-742
109. Paton C, Okocha C I. 2004 Risperidone long-acting injection: the first 50 patients. Psychiatr Bull 28:12-14
110. Paton C, Okocha C I. 2005 Pharmacological treatment ofbor- derline personality disorder. J Psychiatr Intensive Care Psychiatry 1:105-116
111. Peet M, Middlemiss DN, Yates RA. 1980 Pharmacokinetic interaction between propronolol and chlorpromazine in schizophrenic patients. Lancet ii: 978
112. Pereira S, Beer D, Paton C. 1999 When all else fails: a locally devised structured decision process for enforcing clozapine therapy. Psychiatr Bull 23: 654-656
113. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. 1991 Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 148: 231-235
114. Perry PJ, Bever KA, Arndt S, Combs MD. 1998 Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44: 733-738
115. Placidi G F, Lenzi A, Lazzerini F, Cassano G B, Akiskal H S. 1986 The comparative efficacy and safety of carba- mazepine versus lithium: a randomized, double-blind 3- year trial in 83 patients. J Clin Psychiatry 47:490-494
116. Pope H G, McElroy SL, Keck P, Brown S. 1991 Valproate in the treatment of acute mania: a placebo controlled study. Arch Gen Psychiatry 48: 62-68 Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. 1986 Antidepressant effects of carbamazepine. Am J Psychiatry 143: 29-34
117. Post R M, Uhde T W, Roy-Byrne P P, Joffe R T. 1987 Correlates of anti-manic response to carbamazepine. Psychiatr Res 21: 71-83
118. Post RM, Rubinow DR, Uhde TW. 1989 Dysphoric mania: clinical and biological correlates. Arch Gen Psychiatry 46: 353-358
119. Potkin SG, Bera R. 1994 Plasma clozaril concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 55(9): 133-136
120. Puzynski S, Klosiewicz L. 1984 Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 6:115-121
121. Quitkin F, Rifkin A, Klein DF. 1975 Very high dosage versus standard dosage fluphenazine in schizophrenia: a double-blind study of non-chronic treatment refractory patients. Arch Gen Psychiatry 32: 1276-1281
122. Reus V I. 1997 Olanzapine: a novel atypical neuroleptic agent. Lancet 349: 1264-1265
123. Rifkin A, Quitkin F, Carrillo C. 1971 Very high-dose fluphe- nazine for non-chronic treatment refractory patients. Arch Gen Psychiatry 25: 398-403
124. Royal College of Psychiatrists. 1995 The ECT Handbook. Council Report CR 39. London: Royal College of Psychiatrists
125. Sackeim HA. 1994 Central issues regarding the mechanisms of action of ECT: directions for future research. Psychopharmacol Bull 30(3): 281-312
126. Sackeim H A, Prudic J, Devanand D P, Decina P, Kerr B, Malitz S. 1990 The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10: 96-104
127. Sackeim HA, Prudics, Devonod D P. 1993 Effects of stimulus intensity and electrode placement on the efficacy and cognitive effect of electroconvulsive therapy. N Engl J Med 328: 839-846
128. Salzman C. 1980 The use of ECT in the treatment of schizophrenia. Am J Psychiatry 137: 1032-1041
129. Schooler J V R. 1991 Maintenance medication for schizophrenia: strategic for dose reduction. Schizophr Bull 17: 311-324
130. Sernyak M J, Leslie D L, Alarcon R D, Losonczy M F, Rosenheck R. 2002 Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159(4): 561-566
131. Sharif Z. 1998 Treatment of refractory schizophrenia: how should we proceed? Psychiatr Q 69(4): 263-281
132. Sharma R, Trappler B, Ng Y K, Leeman C P. 1995 Risperidone induced neuroleptic malignant syndrome. Ann Pharma- cother 30:775-778
133. Siris S, Bermonzohn PC, Gonzalez A, Manson SE. 1991 Use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27: 331-335
134. Small JG, Klapper MH, Kellams JJ. 1988 Electroconvul- sive treatment compared with lithium in management of manic states. Arch Gen Psychiatry 45: 727
135. Small JG, Klapper MH, Milstein V. 1991 Carbamazepine compared with lithium in treatment of mania. Arch Gen Psychiatry 48: 915-921
136. Squire LR. 1986 Memory functions as affected by electro- convulsive therapy. Ann N Y Acad Sci USA 462: 307-314
137. Tandon R, Harrigan E, Zorn SH. 1997 Ziprasidone: a novel antipsychotic with unique pharmacological and therapeutic potential. J Serotonin Res 4:159-177
138. Taylor D, Duncan D. 1995 The use of clozapine plasma levels in optimising therapy. Psychiatr Bull 19: 753-755
139. Tennent G, Bancroft J, Cass J. 1974 The control of deviant sexual behaviour by drugs: a double blind controlled study of benperidol, chlorpromazine, and placebo. Arch Sex Behar 3: 261-271
140. The Concise Oxford Dictionary. 1995 9th edn. Oxford: Oxford University Press Thompson C. 1994 The use of high-dose antipsychotic medication. Br J Psychiatr 164: 448-458
141. Tohen M, Zhang F, Taylor C C et al. 2001A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 65(1): 85-93
142. Tollefson GD, Beasley CM Jr, Tran PV. 1997 Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective, and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-465
143. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM. 1987 The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 150: 180-182
144. Weiner RD. 1994 Treatment optimization with ECT. Psychopharmacol Bull 30(3): 313-320
145. Weissman M M, Merikangas K R. 1986. The epidemiology of anxiety and panic disorders. J Clin Psychiatry Suppl 47: 11-17
146. West ED. 1981 Electric convulsion therapy in depression: a double blind controlled trial. Br Med J 282: 355-357
147. Wilson WH, Claussen AM. 1994 Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 55: 184-188
148. Winston M. 2000 Recent developments in borderline personality disorder. Adv Psychiatr Treat 6: 211-218
149. Wolkowitz O M, Tureksky N, Reus V I. 1992 Benzodiazepine augmentation of neuroleptics in treatment resistant schizophrenia. Psychopharmacol Bull 28: 291-295
150. Yatham L N. 2003 Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disorders 5(S2): 7-19
151. Yorkston N J, Zaki S A, Pitcher D R, Gruzelier J H, Hollander D, Sergeant H G S. 1977 Propranolol as an adjunct to the treatment of schizophrenics. Lancet ii: 575-578
152. Zanarini M C, Frankenburg F R. 1997 Pathways to the development of borderline personality disoder. J Personal Disord 11(1): 93-104